What Researchers Did
Researchers conducted a systematic review and meta-analysis to evaluate the efficacy and safety of hyperbaric oxygen therapy (HBOT) for inflammatory bowel disease (IBD).
What They Found
The overall response rate for HBOT was 83.24% in ulcerative colitis and 81.89% in Crohn's disease. For fistulizing Crohn's disease, complete fistula healing was observed in 47.64% of patients, with partial healing in 34.29%. Most reported adverse events were minor.
What This Means for Canadian Patients
Hyperbaric oxygen therapy may offer a potential future treatment option for Canadian patients experiencing ulcerative colitis flares or Crohn's disease. However, patients should discuss current evidence with their gastroenterologist, as more definitive research is required before it becomes a standard therapy.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The study's conclusions are limited by the reliance on observational studies and the need for adequately powered randomized controlled trials to draw definite conclusions.